| 1383544-12-4

• CAS: 1383544-12-4
• 化学式: C₁₅H₁₈ClNO₄S
• 分子量: 343.831
• InChiKey: YKEUFCUUVAUAOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.15
• 重原子数：
  22.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  71.52
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  、 2-hydrazinyl-N,N-dimethylaniline 以 甲醇 为溶剂， 反应 18.0h， 生成 2-[5-(4-chlorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)pyrazol-1-yl]-N,N-dimethylaniline
  参考文献：
  名称：

  A novel series of pyrazolylpiperidine N-type calcium channel blockers

  摘要：

  Selective blockers of the N-type calcium channel have proven to be effective in animal models of chronic pain. However, even though intrathecally delivered synthetic x-conotoxin MVIIA from Conus magnus (ziconotide [Prialt (R)]) has been approved for the treatment of chronic pain in humans, its mode of delivery and narrow therapeutic window have limited its usefulness. Therefore, the identification of orally active, small-molecule N-type calcium channel blockers would represent a significant advancement in the treatment of chronic pain. A novel series of pyrazole-based N-type calcium channel blockers was identified by structural modification of a high-throughput screening hit and further optimized to improve potency and metabolic stability. In vivo efficacy in rat models of inflammatory and neuropathic pain was demonstrated by a representative compound from this series. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.075
• 作为产物：
  描述：

  1-(甲基磺酰基)-4-哌啶羰酰氯 、 对氯苯乙酮 在 magnesium bromide ethyl etherate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  A novel series of pyrazolylpiperidine N-type calcium channel blockers

  摘要：

  Selective blockers of the N-type calcium channel have proven to be effective in animal models of chronic pain. However, even though intrathecally delivered synthetic x-conotoxin MVIIA from Conus magnus (ziconotide [Prialt (R)]) has been approved for the treatment of chronic pain in humans, its mode of delivery and narrow therapeutic window have limited its usefulness. Therefore, the identification of orally active, small-molecule N-type calcium channel blockers would represent a significant advancement in the treatment of chronic pain. A novel series of pyrazole-based N-type calcium channel blockers was identified by structural modification of a high-throughput screening hit and further optimized to improve potency and metabolic stability. In vivo efficacy in rat models of inflammatory and neuropathic pain was demonstrated by a representative compound from this series. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.075